Related Experiment Video
Updated: Feb 11, 2026
A Genetic Screen to Isolate Toxoplasma gondii Host-cell Egress Mutants
Published on: February 8, 2012
Antiproliferative Plaque Assay for Screening in vitro Bioactive Molecules against Toxoplasma gondii Tachyzoites
Mike Dos Santos1, Andréia Luiza Oliveira Costa1, Mariana Maciel Cunha1
1Laboratório de Quimioterapia de Protozoários Egler Chiari, Departamento de Parasitologia - ICB, Universidade Federal de Minas Gerais.
Abstract:
Toxoplasmosis is a parasitic infection commonly related to ocular lesions and neonatal malformations. Since the early 1950s, the first-line treatment of this disease has relied on the combination of sulfadiazine, pyrimethamine, and folinic acid. Over those years, only a few alternative regimens have been introduced. This highlights the need for discovering new bioactive molecules against Toxoplasma gondii. Given that this pathogen is an obligate intracellular parasite, traditional drug screening in the laboratory typically requires expensive materials and equipment, such as assays using fluorescent proteins or β-galactosidase-expressing parasites. Additionally, methods like optical microscopy quantification can be time-consuming. The plaque assay is a method that evaluates the intensity of intracellular pathogen proliferation by measuring the number of regions and area of destruction in a cell monolayer damaged by the parasite's lytic cycle. This work describes an optimized plaque assay protocol designed for screening active molecules against intracellular tachyzoites of T. gondii in vitro. This protocol utilizes inexpensive materials and a straightforward laboratory setup, yielding rapid and reproducible results that facilitate the identification of new active molecules against this parasite by various research groups.
Insights
Discovering new treatments for toxoplasmosis (Toxoplasma gondii infection) is crucial. This study optimized an inexpensive and rapid plaque assay for screening novel drug candidates against this intracellular parasite.
Area of Science:
- Parasitology
- Infectious Diseases
- Drug Discovery
Background:
- Toxoplasmosis, caused by *Toxoplasma gondii*, is linked to ocular issues and congenital defects.
- Current treatments, established in the 1950s, lack alternatives, necessitating new drug discovery.
- Screening *T. gondii* drug candidates is challenging due to the parasite's intracellular nature and costly traditional assays.
Purpose of the Study:
- To optimize a cost-effective and efficient *in vitro* plaque assay for *Toxoplasma gondii*.
- To facilitate the screening of novel bioactive molecules against *T. gondii* tachyzoites.
- To provide a reproducible method for identifying new anti-toxoplasmosis agents.
Main Methods:
- Development and optimization of a plaque assay protocol for *T. gondii* tachyzoites.
- Utilized inexpensive laboratory materials and a simple setup.
- Focused on quantifying parasite-induced cell monolayer destruction.
Main Results:
- The optimized plaque assay provides rapid and reproducible results.
- The protocol is designed for ease of use and affordability.
- Successfully demonstrated the assay's utility for screening anti-*T. gondii* molecules.
Conclusions:
- The optimized plaque assay is a valuable tool for discovering new *Toxoplasma gondii* therapeutics.
- This method lowers the barrier for researchers to screen for novel anti-parasitic compounds.
- Enables efficient identification of molecules targeting intracellular tachyzoites.
More Related Videos
Related Concept Videos
02:38Molecules and Compounds
01:32Types of Signaling Molecules
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
03:48Behavior of Gas Molecules: Molecular Diffusion, Mean Free Path, and Effusion
01:45Positive Regulator Molecules
02:39Positive Regulator Molecules